HQ
  • About A*STAR
    • Corporate Profile
      • A*STAR Board Members
      • Senior Management
      • Organisation Structure
      • Corporate Social Responsibility
      • Diversity at A*STAR
      • A*STAR Sustainability
    • Annual Report
    • A*STAR Global Network
  • Research
    • About A*STAR Research
    • Funding Opportunities
    • S-SEAF
    • Research Ethics
    • Biomedical Research Council
    • Science and Engineering Research Council
    • Our People
      • Highly Cited Researchers
      • Honours and Accolades
  • Innovation & Enterprise
    • About I&E
    • Innovation Offerings
  • Scholarships
  • News
    • A*STAR News
      • Publicity Highlights
      • Press Releases
      • Features
      • Committee Of Supply (COS) Debate
    • Case Studies
    • Faces of A*STAR
    • National Survey of RIE
    • Connect with Us
  • Career
  • Home
  • News
  • A*STAR News
  • Publicity Highlights
  • A*STAR News
    • Publicity Highlights
    • Press Releases
    • Features
    • Committee Of Supply (COS) Debate
  • Case Studies
  • Faces of A*STAR
  • National Survey of RIE
  • Connect with Us
Agency for Science, Technology and Research (A*STAR)
PartnershipsCareersSuppliersContact UsWhistleblowing
  • Report Vulnerability
  • Privacy Statement
  • Terms & Conditions
    • Publicity Highlights

    GIS and Invitrocue launch new joint lab to advance personalized medicine for cancer treatment

    24 Jul 2017
    • Whatsapp
    • Telegram
    • Facebook
    • Twitter
    • Email
    • Linked In

    On 24 July 2017, A*STAR’s Genome Institute of Singapore and Invitrocue announced the launch of a joint laboratory that will boost expertise and develop tumour models to enhance decision-making for clinicians, enabling them to personalise treatments that will help patients manage the disease and prolong survival. The joint laboratory will leverage GIS’ expertise in genomics, oncology and organoid biology, and Invitrocue’s capabilities in developing cell-based products and services for commercialisation. The joint laboratory will employ up to 20 personnel in various scientific and technical roles, and targets to add 18 new positions which require cell biology and bioengineering expertise over the next two years.

    Read more below:
    • CNBC Shake It Up: ASX-listed Invitrocue teams up with A*STAR
    • Straits Times: New lab to provide customised cancer treatment